{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:41Z","timestamp":1793915681815,"version":"4.8.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapies such as plasma exchange, IVIG infusions and other immunosuppressive agents. However, there are significant side effects associated with most of these therapies. Since there is a better understanding of the molecular structure and the biological properties of the neonatal Fc receptors (FcRn), it possesses an attractive profile in treating myasthenia gravis. FcRn receptors prevent the catabolism of IgG by impeding their lysosomal degradation and facilitating their extracellular release at physiological pH, consequently extending the IgG half-life. Thus, the catabolism of IgG can be enhanced by blocking the FcRn, leading to outcomes similar to those achieved through plasma exchange with no significant safety concerns. The available studies suggest that FcRn holds promise as a versatile therapeutic intervention, capable of delivering beneficial outcomes in patients with distinct characteristics and varying degrees of MG severity. Efgartigimod is already approved for the treatment of generalized MG, rozanolixizumab is under review by health authorities, and phase 3 trials of nipocalimab and batoclimab are underway. Here, we will review the available data on FcRn therapeutic agents in the management of MG.<\/jats:p>","DOI":"10.3389\/fneur.2023.1229112","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T16:27:54Z","timestamp":1691166474000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["FcRN receptor antagonists in the management of myasthenia gravis"],"prefix":"10.3389","volume":"14","author":[{"given":"Vinaya","family":"Bhandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"Breiner","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer Biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1113\/jphysiol.1964.sp007338","article-title":"Further observations on the distribution of acetylcholine-reactive sites in skeletal muscle","volume":"170","author":"Katz","year":"1964","journal-title":"J Physiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","article-title":"Safety factor at the neuromuscular junction","volume":"64","author":"Wood","year":"2001","journal-title":"Prog Neurobiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis\u2020","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1113\/jphysiol.2010.190298","article-title":"Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice: actions of MuSK autoantibodies in experimental myasthenia gravis","volume":"588","author":"Cole","year":"2010","journal-title":"J Physiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders: autoimmune neuromuscular disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor\u2013related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4 \/agrin-antibody\u2013positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.11477\/mf.1416101472","article-title":"Autoantibodies in myasthenia gravis","volume":"65","author":"Motomura","year":"2013","journal-title":"Shikei kenky\u016b no shinpo"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1600-0404.1977.tb01445.x","article-title":"Genetic aspects in myasthenia gravis: a family study of 264 Finnish patients","volume":"56","author":"Pirskanen","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1375\/twin.14.2.129","article-title":"Utilizing twins concordance rates to infer the predisposition to myasthenia gravis","volume":"14","author":"Ramanujam","year":"2011","journal-title":"Twin Res Hum Genet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/ni0407-333","article-title":"Foxp3 and Aire in thymus-generated Treg cells: a link in self-tolerance","volume":"8","author":"Nomura","year":"2007","journal-title":"Nat Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","article-title":"Thymic germinal centers and corticosteroids in myasthenia gravis: an Immunopathological study in 1035 cases and a critical review","volume":"52","author":"Truffault","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory T cells in myasthenia gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00315656","article-title":"A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy","volume":"237","author":"Mantegazza","year":"1990","journal-title":"J Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis: PLEX in MG","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06767.x","article-title":"IVIG and PLEX in the treatment of myasthenia gravis: IVIG and PLEX in MG","volume":"1275","author":"Bril","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","article-title":"A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis","volume":"9","author":"Jensen","year":"2008","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma-exchange","volume":"308","author":"Pinching","year":"1976","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.cellbio.12.1.181","article-title":"Fc receptors and their interaction with immunoglobulins","volume":"12","author":"Raghavan","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1146\/annurev.bi.48.070179.004525","article-title":"Three-dimensional structure of immunoglobulins","volume":"48","author":"Amzel","year":"1979","journal-title":"Annu Rev Biochem"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev.iy.01.040183.000511","article-title":"Structural basis of antibody function","volume":"1","author":"Davies","year":"1983","journal-title":"Annu Rev Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/0959-440X(94)90267-4","article-title":"Antibody-antigen interactions: new structures and new conformational changes","volume":"4","author":"Wilson","year":"1994","journal-title":"Curr Opin Struct Biol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/08830189709045707","article-title":"Fc receptors as targets for immunotherapy","volume":"16","author":"Rouard","year":"1997","journal-title":"Int Rev Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fc\u03b3-receptor\u2013mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.cellbio.12.1.181","article-title":"Fc receptors and their interactions with immunoglobulins","volume":"12","author":"Raghavan","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s11095-013-1212-3","article-title":"Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis","volume":"31","author":"Hornby","year":"2014","journal-title":"Pharm Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e12972","DOI":"10.1111\/aji.12972","article-title":"Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns","volume":"80","author":"Lozano","year":"2018","journal-title":"Am J Reprod Immunol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1681\/ASN.V114632","article-title":"Characterization and localization of the neonatal fc receptor in adult human kidney","volume":"11","author":"Haymann","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1172\/JCI117934","article-title":"A major histocompatibility complex class I-related fc receptor for IgG on rat hepatocytes","volume":"95","author":"Blumberg","year":"1995","journal-title":"J Clin Invest"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/ajt.15366","article-title":"The neonatal fc receptor: key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am J Transplant"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1021\/bi052628y","article-title":"Albumin binding to FcRn: distinct from the FcRn\u2212IgG interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in \u03b22-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur J Immunol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00109-008-0366-7","article-title":"Neonatal fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita","volume":"86","author":"Sesarman","year":"2008","journal-title":"J Mol Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1212\/01.wnl.0000903308.81107.e2","article-title":"Long-term safety and efficacy of Efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study","volume":"99","author":"Howard","year":"2022","journal-title":"Neurology"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: a phase 2 RCT","author":"Bril","year":"2020","journal-title":"Neurology"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref69","unstructured":""},{"key":"ref70","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.ajog.2019.02.058","article-title":"M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model","volume":"220","author":"Roy","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjh.17041","article-title":"Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation","volume":"192","author":"Castleman","year":"2021","journal-title":"Br J Haematol"},{"key":"ref73","first-page":"2157","article-title":"A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of Nipocalimab administered to adults with generalized myasthenia gravis (2157)Jeffrey Guptill, Carlo Antozzi, Vera Bril, Josep Gamez, Sven G. Meuth, Jose Luis Mu\u00f1oz Blanco, RichardJ. Nowak, Dianna Quan, Teresa Sevilla, Andrzej Szczudlik, Brooke Hegart, Marie-Helene Jouvin, Jim Jin","volume":"96","year":"2021","journal-title":"Santiago Arroyo Neurol"},{"key":"ref74","unstructured":"Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Nipocalimab administered to adults with generalized myasthenia gravis2021"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"CollinsJ JonesL SnyderM SicardE GriffinP WebsterL RVT-1401, a novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration (P 5.2\u2013079)2019","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/cts.13019","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers","volume":"14","author":"Yap","year":"2021","journal-title":"Clin Transl Sci"},{"key":"ref77","unstructured":"A phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension of RVT-1401 in myasthenia gravis patients2021"},{"key":"ref78","unstructured":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and Pharmacodynamic and pharmacokinetic of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis2021"},{"key":"ref79","unstructured":""},{"key":"ref80","unstructured":""}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1229112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T13:33:14Z","timestamp":1702906394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1229112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":80,"alternative-id":["10.3389\/fneur.2023.1229112"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1229112","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"article-number":"1229112"}}